Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia

(2018) Todd A. Fehniger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells

(2018) Yufeng Wang et al.   CLINICAL CANCER RESEARCH

Bispecific antibodies: design, therapy, perspectives

(2018) Sergey Sedykh et al.   Drug Design Development and Therapy

A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism

(2018) Niken M. Mahaweni et al.   Scientific Reports

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

(2018) Alexandra Thomas et al.   OncoImmunology

The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment

(2017) M.A.C. Versluis et al.   EUROPEAN JOURNAL OF CANCER

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients

(2017) M Michallet et al.   LEUKEMIA

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells

(2017) Thorsten Gantke et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy

(2017) Joachim Koch et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

(2017) Jörg U. Schmohl et al.   Cancer Research and Treatment

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

(2017) Tatiana Pazina et al.   OncoImmunology

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

(2017) Kristina Ellwanger et al.   Frontiers in Oncology

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

(2016) U. Reusch et al.   CLINICAL CANCER RESEARCH

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

Identification of high-affinity anti-CD16A allotype-independent human antibody domains

(2016) Wei Li et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy

(2016) Jesus I. Luna et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Neutrophils in cancer

(2016) Louise W. Treffers et al.   IMMUNOLOGICAL REVIEWS

Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa

(2016) Alysia A. Ahmed et al.   JOURNAL OF STRUCTURAL BIOLOGY

Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology

(2016) Amy K. LeBlanc et al.   Science Translational Medicine

Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients

(2016) Bin Xu et al.   Oncotarget

Bispecific antibodies in cancer immunotherapy

(2016) Siqi Chen et al.   Human Vaccines & Immunotherapeutics

Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface

(2016) Jin Hong Kim et al.   Scientific Reports

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

(2015) J. C. Byrd et al.   BLOOD

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

Improving natural killer cell cancer immunotherapy

(2015) Melissa M. Berrien-Elliott et al.   Current Opinion in Organ Transplantation

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT

(2015) F Cichocki et al.   LEUKEMIA

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells

(2015) Uwe Reusch et al.   mAbs

Pharmacokinetic properties of IgG and various Fc fusion proteins in mice

(2015) Felix Unverdorben et al.   mAbs

Macrophages are critical effectors of antibody therapies for cancer

(2015) Kipp Weiskopf et al.   mAbs

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Ebola vaccine R&D: Filling the knowledge gaps

(2015) Donata Medaglini et al.   Science Translational Medicine

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells

(2015) J. U. Schmohl et al.   Targeted Oncology

Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions

(2014) L. Baudino et al.   JOURNAL OF IMMUNOLOGY

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells

(2014) Uwe Reusch et al.   mAbs

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

NK cells and T cells cooperate during the clinical course of colorectal cancer

(2014) Giuseppe Sconocchia et al.   OncoImmunology

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

(2013) Katrin S. Reiners et al.   MOLECULAR THERAPY

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay

(2013) Paul R. Burchard et al.   Cancer Genetics

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

(2012) C. A. Gerdes et al.   CLINICAL CANCER RESEARCH

RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells

(2012) Fionnuala McAleese et al.   Future Oncology

Soluble Monomeric IgG1 Fc

(2012) Tianlei Ying et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

(2011) K.-H. Heider et al.   BLOOD

DARTs take aim at BiTEs

(2011) C. Rader   BLOOD

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service

(2010) Markus Wallwiener et al.   BMC CANCER

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma

(2010) Giuseppe Sconocchia et al.   INTERNATIONAL JOURNAL OF CANCER

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Exposure of NK cells to intravenous immunoglobulin induces IFNγ release and degranulation but inhibits their cytotoxic activity

(2009) Christian Jacobi et al.   CLINICAL IMMUNOLOGY

Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques

(2008) Elisa I. Choi et al.   IMMUNOLOGY